Corcept Therapeutics Incorporated
CORTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Corcept Therapeutics Incorporated focuses on Biotechnology services and products. Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. At a $9.72B market cap, Corcept Therapeutics Incorporated ranks as a mid-cap company within healthcare. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Market Cap
$9.72B
Beta
0.46
P/E (TTM)
258.63
P/E (Fwd)
28.23
EPS (TTM)
$0.35
EPS (Fwd)
$3.21
ROE
7.2%
ROA
-0.6%
Cash
$338.2M
Total Debt
$9.6M
Free CF
$115.7M
52W Change
27.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $338.2M in cash comfortably exceeding the $9.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $115.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 7.2% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $401.9M (2022) to $761.4M (2025), reflecting a 89% increase over the period.
With a beta below 0.7, Corcept Therapeutics Incorporated typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing CORT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.